Raymond James Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raymond James Financial’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Buy	22,863 +2,732	+14%	+$283K	﹤0.01%	3329
2026 Q1	$2.09M	Sell	20,131 -4,976	-20%	-$530K	﹤0.01%	3332
2025 Q4	$2.59M	Buy	25,107 +931	+4%	+$90.6K	﹤0.01%	3072
2025 Q3	$2.18M	Buy	24,176 +1,759	+8%	+$154K	﹤0.01%	3116
2025 Q2	$1.97M	Buy	22,417 +2,363	+12%	+$205K	﹤0.01%	3092
2025 Q1	$1.83M	Buy	20,054 +4,721	+31%	+$425K	﹤0.01%	3051
2024 Q4	$1.32M	Buy	+15,333	New	+$1.39M	﹤0.01%	3260

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Raymond James Financial's PPH Position: Q2 2026 in Review

Raymond James Financial increased its VanEck Pharmaceutical ETF (PPH) stake by 14% in Q2 2026, buying an estimated $283K and bringing the position to 22,863 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Raymond James Financial first reported a position in PPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.59M in Q4 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Raymond James Financial held 22,863 shares of VanEck Pharmaceutical ETF worth $2.5M as of Q2 2026.
Raymond James Financial bought 2,732 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $283K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3329 holding.
Raymond James Financial first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's VanEck Pharmaceutical ETF position peaked at $2.59M in Q4 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.